Good clinical trials need good guidance
Good randomised controlled trials provide reliable evidence that informs changes in healthcare practice. There is a pressing need to make it easier to do good trials that inform improvements in future care.
Alongside establishing Protas, Prof Sir Martin Landray, Protas’ Chief Executive Officer, has been leading the Good Clinical Trials Collaborative (the “Collaborative”) since June 2020 with the aim of driving this change.
Supported by Wellcome, the Bill & Melinda Gates Foundation and the African Academy of Sciences, the aim of the Collaborative is to develop guidance to enable and promote informative, ethical and efficient randomised controlled trials.
The Collaborative has brought together a wide range of individuals and organisations with an interest in and role to play in the design, delivery, analysis and reporting of randomised trials, and in implementing the results.
This includes those who fund, regulate, design, deliver or are responsible for such trials, those who provide audits and quality assurance functions, research organisations, clinicians, participants, ethicists, and lay health advocates.
It includes those from a wide variety of sectors (industry, academia, government, charitable, non-governmental organisations, participant and public groups) and settings.
The Collaborative has recently launched its draft guidance for public consultation, which will be running between 4 August to 15 September 2021.
The team is looking for feedback to help shape the guidance. This work is valuable not only for Protas and its partners but to all who play a role in randomised trials and those who benefit from the results.
